PT2000137E - Agente redutor de triglicerídeos e agente melhorador de hiperinsulinismo - Google Patents

Agente redutor de triglicerídeos e agente melhorador de hiperinsulinismo Download PDF

Info

Publication number
PT2000137E
PT2000137E PT77369734T PT07736973T PT2000137E PT 2000137 E PT2000137 E PT 2000137E PT 77369734 T PT77369734 T PT 77369734T PT 07736973 T PT07736973 T PT 07736973T PT 2000137 E PT2000137 E PT 2000137E
Authority
PT
Portugal
Prior art keywords
agent
hyperinsulinism
triglyceride
ameliorating
lowering
Prior art date
Application number
PT77369734T
Other languages
English (en)
Inventor
Toru Yokoyama
Taro Aoki
Original Assignee
Kowa Co
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co, Nissan Chemical Ind Ltd filed Critical Kowa Co
Publication of PT2000137E publication Critical patent/PT2000137E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
PT77369734T 2006-03-29 2007-03-28 Agente redutor de triglicerídeos e agente melhorador de hiperinsulinismo PT2000137E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006090160 2006-03-29
JP2006204608 2006-07-27

Publications (1)

Publication Number Publication Date
PT2000137E true PT2000137E (pt) 2016-02-17

Family

ID=38540962

Family Applications (1)

Application Number Title Priority Date Filing Date
PT77369734T PT2000137E (pt) 2006-03-29 2007-03-28 Agente redutor de triglicerídeos e agente melhorador de hiperinsulinismo

Country Status (9)

Country Link
US (2) US8124622B2 (pt)
EP (1) EP2000137B1 (pt)
JP (1) JP5330825B2 (pt)
KR (1) KR101381076B1 (pt)
CN (1) CN101415425B (pt)
CA (1) CA2645281A1 (pt)
ES (1) ES2558799T3 (pt)
PT (1) PT2000137E (pt)
WO (1) WO2007111027A1 (pt)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
GT199800127A (es) 1997-08-29 2000-02-01 Combinaciones terapeuticas.
CA2296726C (en) 1997-08-29 2004-06-29 Pfizer Products Inc. Combination therapy
US20020028826A1 (en) 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
EP1314425A4 (en) 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
JP2002145770A (ja) 2000-08-30 2002-05-22 Sankyo Co Ltd 心不全の予防又は治療のための医薬組成物
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
CA2465693A1 (en) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
JP2005089300A (ja) 2003-08-05 2005-04-07 Kowa Co 高脂血症治療剤
CA2546793A1 (en) * 2003-12-16 2005-06-30 Novartis Ag Use of stating for the treatment of metabolic syndrome
WO2005097191A2 (en) 2004-04-04 2005-10-20 Sepracor Inc. COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION

Also Published As

Publication number Publication date
EP2000137B1 (en) 2015-10-21
US20090291980A1 (en) 2009-11-26
EP2000137A2 (en) 2008-12-10
KR20080105119A (ko) 2008-12-03
US20120095043A1 (en) 2012-04-19
JPWO2007111027A1 (ja) 2009-08-06
US8124622B2 (en) 2012-02-28
EP2000137A9 (en) 2009-03-18
CA2645281A1 (en) 2007-10-04
EP2000137A4 (en) 2010-02-24
ES2558799T3 (es) 2016-02-08
CN101415425B (zh) 2014-11-26
US8604054B2 (en) 2013-12-10
CN101415425A (zh) 2009-04-22
JP5330825B2 (ja) 2013-10-30
KR101381076B1 (ko) 2014-04-02
WO2007111027A1 (ja) 2007-10-04

Similar Documents

Publication Publication Date Title
ZA200810323B (en) Fkbp-l and uses thereof
PL2064327T3 (pl) Dbait i ich zastosowania
HK1208000A1 (en) Thioninium compounds and their use
GB0621160D0 (en) Compounds and uses thereof
HK1133552A1 (en) Carboranylporphyrins and uses thereof
GB0611115D0 (en) Compounds and their use
GB0605107D0 (en) Use
EP2077262A4 (en) IMINOPYRIDINE DERIVATIVES AND THEIR USE
EP2062892A4 (en) AGENT ENHANCING HYPERTENSION
EP2124908A4 (en) CONNECTIONS AND ITS USE
EP2120563A4 (en) CONNECTIONS AND ITS USES
EP2030629A4 (en) AGENT FOR IMPROVING LIPID METABOLISM
EP2069371A4 (en) ORGANO ARSENOXIDE COMPOUNDS AND THEIR USE
GB0624105D0 (en) Use
EP2060263A4 (en) AGENT FOR IMPROVING LIPID METABOLISM
GB0619611D0 (en) Compounds and their use
GB0610059D0 (en) Uses and methods
EP2099459A4 (en) COMPOUNDS AND USES THEREOF
EP2120957A4 (en) COMPOUNDS AND USES THEREOF
EP2000137A4 (en) AGENT PROMOTING THE DROP OF TRIGLYCERIDES AND AGENT ENHANCING HYPERINSULINISM
GB2444960B (en) Combined pseudoscope and hyperscope
GB0621665D0 (en) Blogmail and podmail
GB0606794D0 (en) Methods and uses
EP2057992A4 (en) MEANS FOR IMPROVING THE KIDNEY FUNCTION
GB0615557D0 (en) Compounds and Uses Thereof